Home / Drug News / Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis

Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the plaque psoriasis drug guselkumab (Tremfya, Janssen-Cilag International NV) for approval.

The CHMP supported the use of guselkumab for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy, according to an EMA news release.

“We are pleased guselkumab may soon be available to adults living with moderate to severe plaque psoriasis in Europe, because the evidence shows this novel therapeutic offers significant and lasting efficacy for patients in need of alternative treatment options,” said José Antonio Burόn Vidal, Janssen vice president of medical affairs, Europe, Middle East, and Africa, in a statement.

The company said that 14 million people in Europe have plaque psoriasis.

Full Article

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

SculpSure FDA approved

FDA expands indications for SculpSure

The U.S. Food and Drug Administration granted an expanded FDA 510(k) clearance in September for Cynosure’s non-invasive body contouring product, SculpSure. This body contouring laser treatment is now cleared to treat the submental area. SculpSure has also been cleared to treat the abdomen, flanks, back, and inner and outer thighs. This treatment uses a laser …

Leave a Reply

Your email address will not be published. Required fields are marked *